Clinical trials
Cancer (Advanced Stage) clinical trials
Below are recruiting cancer (advanced stage) clinical trials, each written for real people, not researchers. We’re tracking 1,008 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06123754RecruitingPhase 3
Envafolimab plus chemo for stage III NSCLC before surgery
This trial tests a new immunotherapy (Envafolimab) combined with standard chemotherapy before and after surgery for stage III non-small cell lung cancer that can be removed. The goal is to see if adding Envafolimab helps shrink the tumor and improve outcomes compared to chemotherapy alone.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06088771RecruitingPhase 1/Phase 2
Study of dupilumab and cemiplimab before lung cancer surgery
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
New York, New YorkAges 18 years+ - NCT06370416Enrolling by invitationPhase 2
Preventing bone marrow suppression from chemo in advanced lung cancer
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
Zhengzhou, HenanAges 18 years+ - NCT05401110RecruitingPhase 1
Osimertinib plus antibody treatment for EGFR-mutated lung cancer
This Phase 1 study tests the combination of osimertinib (a targeted lung cancer pill) with an antibody called carotuximab to treat advanced EGFR-mutated non-small cell lung cancer. It aims to see whether adding the antibody can help when the cancer has grown despite prior EGFR-targeted therapy.
Beverly Hills, CaliforniaAges 18 years+ - NCT07631793RecruitingPhase 1
Experimental vaccine for advanced solid tumors
This trial tests an experimental vaccine called YKYY031 for people with advanced solid tumors that have stopped responding to standard treatments. The vaccine aims to help your immune system fight cancer cells that carry specific markers. It may be an option if you have certain genetic markers and tumor proteins.
Beijing, Beijing MunicipalityAges 18–75 - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Tucson, ArizonaAges 18 years+ - NCT03454035RecruitingPhase 1
Combination of two study drugs for advanced pancreatic and other solid tumors
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
Chapel Hill, North CarolinaAges 18–99 - NCT06305715RecruitingPhase 2
Radiation before targeted therapy for advanced lung cancer
This trial tests if giving radiation to the main lung tumor before starting a targeted therapy pill can help delay the cancer from growing. It is for people with advanced non-small cell lung cancer that has a specific genetic change and who have not had targeted therapy before.
Milwaukee, WisconsinAges 18 years+ - NCT06427941RecruitingPhase 1/Phase 2
Study of BGB-B2033 with other drugs for advanced solid tumors
This study tests a new drug called BGB-B2033, alone or with other drugs (tislelizumab and bevacizumab), in people with certain advanced cancers. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
Birmingham, AlabamaAges 18 years+ - NCT04975152RecruitingPhase 1
Cemiplimab before surgery for Merkel cell and skin cancers
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
Tampa, FloridaAges 18 years+ - NCT06417008RecruitingPhase 2/Phase 3
Combination targeted therapy for advanced EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (HS-20117 and aumolertinib) in people with advanced EGFR-mutant lung cancer who haven't had treatment yet. The goal is to see if the combination works better than current standard treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06437977RecruitingPhase 3
Pre-surgery treatment with radiation, immunotherapy, and chemo for stage II-III NSCLC
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
ShanghaiAges 18–75 - NCT06611137RecruitingPhase 2
SBRT plus chemoimmunotherapy to save the voice box
This trial tests a new approach to treat advanced larynx or hypopharynx cancer without removing the voice box. First, you get targeted radiation (SBRT), then a combination of chemotherapy and an immunotherapy drug called Toripalimab, which helps your immune system fight the cancer.
Guangzhou, GuangdongAges 18–70 - NCT05473156RecruitingPhase 1/Phase 2
Study of AP203 for advanced solid tumors that grew despite treatment
This early-phase study tests AP203 (an investigational treatment) to see if it is safe and to look for signs it can shrink or control certain advanced cancers. The study includes a dose-finding part for many solid tumors, and a second part focused on specific lung and head/neck cancers that previously received PD-1/PD-L1 therapy.
TaipeiAges 18 years+ - NCT06749886RecruitingPhase 2
Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
ShanghaiAges 18 years+ - NCT06574347RecruitingPhase 2
Two targeted drugs for EGFR-mutated, MET-high lung cancer
This trial tests a combination of two targeted drugs (vebreltinib and PLB1004) as the first treatment for people with a specific type of advanced lung cancer that has both an EGFR mutation and high MET protein. It may offer a new option for those who haven't had treatment yet.
Guangzhou, GuangdongAges 18 years+ - NCT07058519RecruitingPhase 2
Personalized osimertinib treatment guided by blood test for EGFR lung cancer
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07002216RecruitingPhase 2
BrECADD therapy for stage 2B to stage 4 Hodgkin lymphoma
This trial tests a combination drug treatment called BrECADD for people with Hodgkin lymphoma that has certain risk factors or is in a more advanced stage (stage 2B, 3, or 4). It aims to see if this treatment works well and is safe.
Miami, FloridaAges 18–60 - NCT06929936RecruitingPhase 2
Trilaciclib plus docetaxel for advanced lung cancer (second-line+)
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
Xiamen, FujianAges 18 years+ - NCT06043427RecruitingPhase 2
Testing paclitaxel and ramucirumab with or without zanidatamab for HER2+ stomach cancer
This trial tests adding a new drug (zanidatamab) to standard chemotherapy (paclitaxel and ramucirumab) for people with advanced HER2-positive stomach, gastroesophageal junction, or esophageal cancer that has worsened after previous treatment. It aims to see if the combination works better.
Calgary, AlbertaAges 18 years+ - NCT05498792RecruitingEarly Phase 1
Trial testing CBL0137 with two immunotherapy drugs for melanoma
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06735391RecruitingPhase 3
JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
GuangzhouAges 18 years+
Hear when a new Cancer (Advanced Stage) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer (advanced stage)?
- Yes. Clin2 currently lists 1,008 recruiting cancer (advanced stage) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer (advanced stage) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer (advanced stage) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.